Milk thistle: Silybum marianum

American Journal of Health-System Pharmacy

Volumn 56, Issue 12, 1999, Pages 1195-1197

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33750263327     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Flora K, Hahn M, Rosen H et al. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol. 1998; 93:139-43.
2. Luper S. A review of plants used in the treatment of liver disease: part 1. Altern Med Rev. 1998; 3:410-21.
3. Zi X, Feyes DK, Agarwal R. Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins. Clin Cancer Res. 1998; 4:1055-64.
4. Zi X, Grasso AW, Kung HJ et al. A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells. Cancer Res. 1998; 58:1920-9.
5. Lahiri-Chatterjee M, Katiyar SK, Mohan RR et al. A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model. Cancer Res. 1999; 59:622-32.
6. Bosisio E, Benelli C, Pirola O. Effect of the flavanolignans of Silybum marianum L. on lipid peroxidation in rat liver microsomes and freshly isolated hepatocytes. Pharmacol Res. 1992; 25:147-54.
7. Koch HP, Bachner J, Loffler E. Silymarin: potent inhibitor of cyclic AMP phosphodiesterase. Methods Find Exp Clin Pharmacol. 1985; 7:409-13.
8. Boigk G, Stroedter L, Herbst H et al. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology. 1997; 26:643-9.
9. Dehmlow C, Erhard J, de Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology. 1996; 23:749-54.
10. Takahara E, Ohta S, Hirobe M. Stimulatory effects of silibinin on the DNA synthesis in partially hepatectomized rat livers: non-response in hepatoma and other malignant cell lines. Biochem Pharmacol. 1986; 35:538-41.
11. The review of natural products. St. Louis: Facts and Comparisons; 1997(Jan):1-6.
12. Weyhenmeyer R, Mascher H, Birkmayer J. Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. Int J Clin Pharmacol Ther Toxicol. 1992; 30(4):134-8.
13. Schandalik R, Gatti G, Perucca E. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. Arzneimittelforschung, 1992; 42:964-8.
14. Magliulo E, Gagliardi B, Fiori GP. Results of a double blind study on the effect of silymarin in the treatment of acute vital hepatitis, carried out at two medical centres [author's transl]. Med Klin. 1978; 73(28-29):1060-5.
15. Floersheim GL, Weber O, Tschumi P et al. Clinical death-cap (Amanita phalloides) poisoning: prognostic factors and therapeutic measures. Analysis of 205 cases. Schweiz Med Wochenschr. 1982; 112:1164-77.
16. Hruby K, Csomos G, Fuhrmann M et al. Chemotherapy of Amanita phalloides poisoning with intravenous silibinin, Hum Toxicol. 1983; 2(2):183-95.
17. Ferenci P, Dragosics B, Dittrich H et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol. 1989; 9(1):105-13.
18. Albrecht M, Frerick H. Therapy of toxic liver pathologies with Legalon. Z Klin Med. 1992; 47:87-92.
19. Feher J, Deak G, Muzes G et al. Hepatoprotective activity of silymarin (Legalon) therapy in patients with chronic liver disease. Orvosi Hetilap. 1989; 130:2723-7.
20. Salmi HA, Sarna S. Effect of silymarin on chemical, functional, and morphological alterations of the liver. A double-blind controlled study. Scand J Gastroenterol. 1982; 17:517-21.
21. Trinchet I, Coste T, Levy VG et al. Treatment of alcoholic hepatitis with silymarin. A double-blind comparative study in 116 patients. Gastroenterol Clin Biol. 1989; 13:120-4.
22. Pares A, Planas R, Torres M et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol. 1998; 28: 615-21.
23. Murray M. The healing power of herbs. 2nd ed. Rocklin, CA: Prima; 1995:243-52.
24. An adverse reaction to the herbal medication milk thistle (Silybum marianum). Med J Aust. 1999; 170:218-9.
25. Brinker F. Herb contraindications and drug interactions. 2nd ed. Sandy, OR: Eclectic Medical; 1998:103-4,190.